ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events

Item 8.01 Other Events.

On June6, 2017, Adaptimmune Therapeutics plc (the Company or
Adaptimmune) hosted a live teleconference and webcast slide
presentation from 8:009:00 AM EDT (1:002:00 PM BST) to discuss
updated data from its NY-ESO study in synovial sarcoma. This
teleconference follows an oral presentation on June5, 2017, at
the 2017 ASCO annual meeting in Chicago,Illinois, entitled, Open
label, non-randomized, multi-cohort pilot study of genetically
engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2 patients
with synovial sarcoma (NCT01343043), when Dr.Sandra P. DAngelo of
the Memorial Sloan Kettering Cancer Center presented an update on
all cohorts from Adaptimmunes ongoing study of NY-ESO SPEAR
T-cells in patients with synovial sarcoma.

The Companys slide presentation materials for the webinar on
June6th are attached as Exhibit99.1 and incorporated by reference
herein.

The information contained in Item 8.01 of this Form8-K, including
the attached Exhibit99.1, shall not be deemed filed for purposes
of Section18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any filing
made by the Company under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by the Company
by specific reference in such a filing.

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits. The following exhibit is furnished as part of this
Report on Form8-K:

About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.